Sintx Technologies Inc Stock Price, News & Analysis

SINTX Technologies (NASDAQ: SINT), a biomedical ceramics company, has announced the successful exercise of warrants resulting in $3.8 million in gross proceeds. The transaction involves the immediate exercise of warrants to purchase 1,099,431 shares at $3.32 per share, originally issued in February 2025.

In exchange for the exercise, the company will issue new unregistered warrants for 1,649,147 shares with an exercise price of $4.79 per share, exercisable immediately with a 5.5-year expiration. H.C. Wainwright & Co. serves as the exclusive placement agent, and SINTX plans to use the proceeds for working capital purposes.

SINTX Technologies (NASDAQ: SINT) has received a USPTO Notice of Allowance for its "Antipathogenic Fibrous Materials" patent application, marking a crucial milestone for its silicon nitride-based antipathogen platform. The patent provides broad protection for using silicon nitride in multiple applications targeting the $30 billion global infection-prevention market.

The technology has demonstrated remarkable efficacy, achieving ~99.97% reduction of multiple coronavirus lineages within 10 minutes and complete inactivation by 30 minutes in laboratory tests. The patent enables applications across medical devices, surgical care, wound management, filtration, PPE, and healthcare infrastructure, addressing the critical challenge of healthcare-associated infections (HAIs) that affect 1 in 31 U.S. hospital patients.

SINTX plans to pursue strategic partnerships and licensing agreements for commercialization, targeting immediate opportunities in wound dressings, surgical drapes, and high-touch clinical environments, with longer-term applications in implant coatings and filtration media.

SINTX Technologies (NASDAQ: SINT) has published groundbreaking research demonstrating its silicon nitride (Si₃N₄) material's powerful antiviral properties against multiple virus strains, including SARS-CoV-2 and MERS-CoV. The study showed up to 99.97% reduction in SARS-CoV-2 within 10 minutes of contact.

As the only FDA-cleared and ISO-certified silicon nitride manufacturer in the U.S., SINTX is targeting the infection-prevention market, estimated to reach $230 billion by 2032. The company aims to commercialize applications in wound care, surgical equipment, PPE, and medical textiles. Silicon nitride offers advantages over traditional antimicrobials, being non-toxic to mammalian cells while effectively neutralizing pathogens.

SINTX Technologies (NASDAQ: SINT), a leader in silicon nitride ceramics for medical devices, has announced significant strategic developments following its acquisition of SiNAPTIC Surgical in July 2025. The company has undergone major restructuring, including leadership expansion and operational streamlining.

Key developments include the successful implantation of over 50,000 spinal interbody devices through CTL/Amedica partnership, and expansion of their product portfolio with 510(k)-cleared interbody spinal implants and pending approval for foot and ankle fusion wedges. The company has strengthened its leadership team with the addition of four key executives from SiNAPTIC.

SINTX has divested non-core assets, including the sale of TA&T subsidiary and closure of its armor ceramics facility, to focus on high-margin medical device opportunities. Despite a slight revenue decrease in Q2 2025, this aligns with their strategic exit from low-margin OEM manufacturing.

SINTX Technologies (NASDAQ: SINT) has announced a breakthrough in biomaterial development, publishing a peer-reviewed study validating silicon nitride (Si₃N₄) surface coatings on carbon fiber-reinforced polyetherketoneketone (CFR-PEKK) trauma plates. The research, supported by NIH-NIAMS and conducted with Drexel University, demonstrates successful integration of silicon nitride into 3D-printed continuous carbon fiber PEKK composites.

The study revealed two key achievements: the hybrid-manufactured CFR-PEKK trauma plates matched the mechanical stiffness of cortical bone, and the Si₃N₄ coating maintained mechanical performance while potentially offering enhanced osseointegration and antimicrobial properties. This development expands SINTX's biomaterial platform into additively-manufactured polymer-carbon-ceramic constructs, with potential applications in orthopedic trauma, spine, and custom surgical implants.

SINTX Technologies (NASDAQ: SINT) has submitted a 510(k) premarket notification to the FDA for its innovative silicon nitride osteotomy wedges, marking its entry into the $750.5 million foot and ankle fusion market. The company's proprietary silicon nitride (Si₃N₄) technology has already been used in over 50,000 spinal interbody fusion devices since 2008.

The new implants offer key advantages including pro-osteogenic properties, antimicrobial capabilities without additives, and superior radiographic clarity. SINTX's solution combines advanced biomaterial science with disposable instrumentation, targeting a market expected to reach $1.38 billion by 2032.

This strategic launch follows SINTX's recent acquisition of SiNAPTIC Surgical on July 1, 2025, positioning the company for significant revenue growth in both hospital and ambulatory surgery center settings.

SINTX Technologies (NASDAQ: SINT) has announced the acquisition of SiNAPTIC Holdings' surgical business assets, marking a strategic move into the $1.3B foot and ankle fusion market. The deal includes six differentiated foot and ankle implant systems, complete with intellectual property and product designs.

The transaction, valued at $750,000 in common shares at $3.465 per share, includes 325,000 performance-based warrants. Key SiNAPTIC executives will join SINTX's leadership team, bringing expertise in product development, regulatory strategy, and commercialization. The global ankle fusion market is projected to grow from $750.5M to $1.38B by 2032, with a 9.1% CAGR.

SINTX Technologies (NASDAQ: SINT), the only FDA-registered producer of implantable silicon nitride, has announced a strategic vision to accelerate commercialization following its February 2025 recapitalization. The company pioneered FDA-cleared silicon nitride implants in 2008, with over 50,000 spinal implants placed worldwide. SINTX holds 18 U.S. patents and 84 pending applications, targeting the $62 billion global orthopedic implant market. Under CEO Eric Olson's leadership, SINTX is developing hybrid biomaterials combining silicon nitride with polymers for spine, oral/maxillofacial, and oncologic reconstruction applications. The company's strategy focuses on joint ventures, IP monetization through licensing, and enhancing AI-supported 3D manufacturing capabilities at its FDA-cleared facility.

SINTX Technologies (NASDAQ: SINT) has announced a strategic transformation from an industrial-ceramics business to a focused medical device innovator, leveraging its silicon nitride technology. The company reported $6.5 million cash on hand as of March 31, 2025, nearly doubled from $3.6 million, bolstered by a $5.0 million private placement in February 2025. SINTX has significantly reduced its operating cash burn from $2.7M to $1.3M year-over-year. The company is streamlining operations through the sale of TA&T subsidiary, shutdown of its Armor subsidiary, and lease liability negotiations. SINTX's strategic focus includes expanding silicon nitride applications in medical markets, including orthopedic implants, spinal fusion devices, dental products, and medical textiles. The company maintains the only FDA-registered and ISO 13485 certified silicon nitride ceramic manufacturing facility.